title: Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients.
abstract: BACKGROUND
  Toxic epidermal necrolysis is a rare disease with high mortality due to generalised infection, sepsis or lung involvement, and requires discontinuation of all potentially triggering medications and intensive care in a specialised burn centre. Apart from wound care with antiseptics, wound coverage may be achieved with a skin substitute; treatments are compared with regard to infection, protein loss, re-epithelialisation and mortality.
  
  
  METHODS
  Of 14 people with toxic epidermal necrolysis affecting >30% body surface area, eight received daily dressing changes using Lavasept nd six received wound coverage with Biobrane. Demographic data, SCORTEN score, mortality, visual-analog pain scale, mobilisation, time to re-epithelialisation, serum protein, albumin, C-reactive protein and leukocytes, and body temperature were evaluated in all cases.
  
  
  RESULTS
  Mean age of patients was 68.0+/-14.8 years, mean body surface area affected was 66.4%, median SCORTEN score was three and overall mortality was 36%. In the Biobrane ompared with the Lavasept control) group, mean pain was significantly reduced (2.9 versus 5.5 on the scale, p<0.05), mobilisation was significantly earlier (walking at 3 days versus 7 days, p=0.003), re-epithelialisation was complete in 12.5 days versus 16 days, and at 9 days there was reduced decrease of serum proteins and significantly lower levels of C-reactive protein and white cells (p<0.05).
  
  
  CONCLUSIONS
  Early wound coverage with synthetic skin substitute such as Biobrane s beneficial compared with conservative antiseptic wound treatment, but mortality rate is not significantly different.
authors.affiliation: Department of Plastic, Hand and Reconstructive Surgery, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Boorboor
authors.forename: P M
authors.initials: PM
authors.lastname: Vogt
authors.forename: F G
authors.initials: FG
authors.lastname: Bechara
authors.forename: Q
authors.initials: Q
authors.lastname: Alkandari
authors.forename: M
authors.initials: M
authors.lastname: Aust
authors.forename: A
authors.initials: A
authors.lastname: Gohritz
authors.forename: M
authors.initials: M
authors.lastname: Spies
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002056:Burns / Q000628:therapy*; D016022:Case-Control Studies; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D004434:Early Ambulation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000517:prevention & control*; D013262:Stevens-Johnson Syndrome / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: C042816:Biobrane; D020099:Coated Materials, Biocompatible